Patents Assigned to MaBel GmbH
  • Uses for 4,17?-dihydroxyandrost-4-ene-3-one
    Patent number: 9610292
    Abstract: The present invention relates to novel uses of 4,17?-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of breast cancer in mammals irrespective of the estrogen-receptor status of the tumor.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: April 4, 2017
    Assignee: MaBel GmbH
    Inventors: Alexander Tobias Teichmann, Heinrich Wieland
  • Uses for 4, 17ß-dihydroxyandrost-4-ene-3-one
    Publication number: 20160030448
    Abstract: The present invention relates to novel uses of 4,17?-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of breast cancer in mammals irrespective of the estrogen-receptor status of the tumor.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Applicant: MaBel GmbH
    Inventors: Alexander Tobias Teichmann, Heinrich Wieland
  • Uses for 4,17?-dihydroxyandrost-4-ene-3-one
    Patent number: 9138477
    Abstract: The present invention relates to novel uses of 4,17?-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of breast cancer in mammals irrespective of the estrogen-receptor status of the tumor.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: September 22, 2015
    Assignee: MaBel GmbH
    Inventors: Alexander Tobias Teichmann, Heinrich Wieland
  • Medication against breast cancer and related diseases
    Patent number: 9114163
    Abstract: The present invention relates to novel uses of a steroid compound, which specifically binds to the androgen receptor (AR) but which is not metabolized by aromatase to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of hormone-dependent or hormone receptor regulated cancers in mammals.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: August 25, 2015
    Assignee: MaBel GmbH
    Inventors: Alexander Tobias Teichmann, Heinrich Wieland